Grace Halsey

AAAAI 2025. Treatment response rates with daily use of the VIASKIN peanut patch increased from 39% at baseline to 73.3% at 60 months in youth aged 4 to 11 years.

Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.

A review of 4 factors can help primary care clinicians with an initial decision about adult vaccination: Health, Age, Lifestyle, and Occupation, or HALO.

Fentanyl overdoses increasingly reveal combined use of stimulants including cocaine and methamphetamine, according to the 2025 update.

Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.

Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.

An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.

AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.

Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.

Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.

Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.

GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

Suzetrigine (Journavx) PI Todd Bertoch, MD, identifies the sweet spot where he thinks the new NaV1.8 inhibitor will be most effective in post-surgical and other moderate-to-severe acute pain.

The global burden of migraine rose by 58% between 1990 and 2021 to more than 1 billion, a pace projected to continue and most rapidly among men and young people.

Robert Hopkins, Jr, MD, says of official communications during the COVID-19 pandemic that not enough was explained to the public about policy shifts, leaving people wondering.

The pivotal INTERCEPT and MOMENTUM phase 3 clinical trials served as foundational evidence for the efficacy of the combination therapy across migraine presentations.

Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.

Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.

Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.

A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.

Although the study missed the primary endpoint, subgroup analyses found variable efficacy based on baseline BECs, suggesting potential benefits in specific subgroups.

Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.